Literature DB >> 1744437

The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography.

T Homma1, R Tsuchiya.   

Abstract

To investigate the possibility of detecting carcinomas of the pancreas at an early stage by mass screening of persons without symptoms or by screening the outpatients with gastrointestinal complaints or jaundice, we performed a multicentral study of the mass screening of 10,162 persons at five local areas and of the outpatient screening of 4506 at 17 hospitals for pancreatic cancer in Japan for two years from 1984 to 1985, using serum CA19-9 and elastase-1 determinations or ultrasonography. Mass screening of 10,162 persons over 40 years old found only four (0.04%) cases of pancreatic cancer, including one case that was curatively treated. According to the screening of 4506 outpatients with gastrointestinal complaints or icterus, 85 (1.9%) patients were found to have pancreatic cancer. Of these 85 patients, 28 could undergo curative treatment. In addition to them, 73 (1.6%) patients with other digestive organ cancer were found. Our results suggest that the mass screening of persons without symptoms is not worthwhile in the early detection of pancreatic cancer, but outpatient screening is useful for detecting curative cancers of the pancreas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744437     DOI: 10.1007/bf02925587

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  5 in total

1.  [Immunological and physicochemical properties of new tumor marker for pancreatic cancer, KM01, detected by monoclonal antibody].

Authors:  H Ohyanagi; T Ishida; K Uesaka; H Ishida; M Yamamoto; S Okumura; Y Saitoh; R Yamanaka; T Kobayashi; K Fukuyama
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1985-06

2.  Noninvasive diagnosis of advanced pancreatic cancer by real-time ultrasonography, carcinoembryonic antigen, and carbohydrate antigen 19-9.

Authors:  T H Wang; J T Lin; D S Chen; J C Sheu; J L Sung
Journal:  Pancreas       Date:  1986       Impact factor: 3.327

3.  The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients.

Authors:  T Frebourg; E Bercoff; N Manchon; J Senant; J P Basuyau; P Breton; A Janvresse; P Brunelle; J Bourreille
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

4.  Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.

Authors:  W M Steinberg; R Gelfand; K K Anderson; J Glenn; S H Kurtzman; W F Sindelar; P P Toskes
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

5.  Sensitive serum markers for detecting pancreatic cancer.

Authors:  T Hayakawa; T Kondo; T Shibata; H Hamano; M Kitagawa; Y Sakai; H Ono
Journal:  Cancer       Date:  1988-05-01       Impact factor: 6.860

  5 in total
  14 in total

Review 1.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 2.  Endoscopic ultrasonography in the diagnosis and staging of pancreatic neoplasms.

Authors:  P Protiva; A V Sahai; B Agarwal
Journal:  Int J Gastrointest Cancer       Date:  2001

Review 3.  Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group.

Authors:  P Pérez Segura; C Guillén Ponce; T Ramón Y Cajal; R Serrano Blanch; E Aranda
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

Review 4.  Update on familial pancreatic cancer.

Authors:  Ralph H Hruban; Marcia I Canto; Michael Goggins; Richard Schulick; Alison P Klein
Journal:  Adv Surg       Date:  2010

Review 5.  Screening and early detection of pancreatic cancer in high risk population.

Authors:  Ming-Chu Chang; Jau-Min Wong; Yu-Ting Chang
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

Review 7.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

Review 8.  Strategies for early detection of resectable pancreatic cancer.

Authors:  Keiichi Okano; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.

Authors:  S Kawa; M Tokoo; O Hasebe; K Hayashi; H Imai; H Oguchi; K Kiyosawa; S Furuta; T Homma
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

10.  Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.

Authors:  J Zhao; Y Liang; Q Yin; S Liu; Q Wang; Y Tang; C Cao
Journal:  Braz J Med Biol Res       Date:  2016-07-25       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.